Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs GoPro Inc (GPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs GoPro Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while GoPro Inc trades at $0.63 (market cap $114.41M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 258.7× GoPro Inc's market cap. Which is the better fit depends on your goals.
| ALNY | GPRO | |
|---|---|---|
Market Cap | $29.60B | $114.41M |
Sector | Health | Technology |
52-Week High | $491.22 | $2.88 |
52-Week Low | $205.48 | $0.62 |
Enterprise Value | $27.56B | $173.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
GoPro (GPRO) trades at $0.58, down 17.87% amid ongoing financial challenges. The company reported Q2 2026 revenue of $105 million with negative earnings, continuing a trend of revenue decline from $1.1B in 2022 to $652M in 2025. Technical indicators show bearish momentum with RSI at oversold levels, while fundamentals reveal negative net income margins and cash flow concerns despite low valuation multiples.
The outlook remains highly speculative with a strategic sale process underway. Investment opportunity exists only for event-driven speculators betting on acquisition potential, while significant risks include going concern warnings, persistent cash burn, and competitive pressures in the action camera market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About GoPro Inc
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →
